Biopharmaceutical benchmarks 2014

Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.

Saved in:

Bibliographic Details
Published in:	Nature biotechnology 2014-10, Vol.32 (10), p.992-1000
Main Author:	Walsh, Gary
Format:	Article
Language:	English
Subjects:	631/154/155 631/154/51/1568 631/154/51/1868 631/154/51/391 Agriculture Analysis Animals Antibodies, Monoclonal Benchmarks Bioinformatics Biological products Biomedical Engineering/Biotechnology Biomedical Research Biomedicine Biopharmaceutics Biosimilar Pharmaceuticals Biotechnology Biotechnology - organization & administration Biotechnology - trends Drug Approval Drug Industry - organization & administration Drug Industry - trends Europe FDA approval feature Gene therapy Genetic Therapy Humans Ingredients Life Sciences Mice Monoclonal antibodies Polyethylene glycol Proteins Surveys United States Vaccines
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!